BIRC3 deletions and mutations are rare albeit unfavorable events for CLL patients that can be also associated to fludarabine-chemoresistance and to adverse prognosis in some chemotherapy-treated CLL patients [55,57]. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.